Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | DHPS | P49366 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8367813 | 0.95 | HDAC2 (0.50) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL21446806 | 0.83 | HDAC1 (0.59) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL21446755 | 0.81 | TSHR (0.60) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2843748 | 0.79 | BCL2L1 (0.62) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL12663172 | 0.77 | HDAC2 (0.70) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL28885145 | 0.75 | HDAC1 (0.68) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8162705 | 0.74 | HDAC1 (0.56) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL1853197 | 0.73 | HDAC1 (0.70) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15228071 | 0.72 | DHPS (0.58) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29874896 | 0.72 | HDAC1 (1.00) | HDAC2HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | claimed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | claimed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | claimed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | claimed |
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | disclosed |
| US-6673788-B2 | CONTAINING 2,2,2-TRIFLUORO-1-OXOETHYL GROUPS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-6673784-B1 | HALOSUBSTITUTED ACETOPHENONES AS SELECTIVE HERPESVIRUS PROTEASE INHIBITORS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | disclosed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | HDAC2 335/4885HDAC1 903/4885HDAC3 601/4885 |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | HDAC2 335/4885HDAC1 903/4885HDAC3 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.